AU2001251330A1 - Halogenated triphenylethylene derivatives as selective estrogen receptor modulators - Google Patents

Halogenated triphenylethylene derivatives as selective estrogen receptor modulators

Info

Publication number
AU2001251330A1
AU2001251330A1 AU2001251330A AU5133001A AU2001251330A1 AU 2001251330 A1 AU2001251330 A1 AU 2001251330A1 AU 2001251330 A AU2001251330 A AU 2001251330A AU 5133001 A AU5133001 A AU 5133001A AU 2001251330 A1 AU2001251330 A1 AU 2001251330A1
Authority
AU
Australia
Prior art keywords
group
alkyl
compound
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251330A
Other languages
English (en)
Inventor
Robert F. Kaltenbach
George L. Trainor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001251330A1 publication Critical patent/AU2001251330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001251330A 2000-04-05 2001-04-05 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators Abandoned AU2001251330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19457900P 2000-04-05 2000-04-05
US60194579 2000-04-05
PCT/US2001/011080 WO2001077057A2 (fr) 2000-04-05 2001-04-05 Derives de triphenylethylene halogene utiles en tant que modulateurs selectifs vis-a-vis du recepteur des oestrogenes

Publications (1)

Publication Number Publication Date
AU2001251330A1 true AU2001251330A1 (en) 2001-10-23

Family

ID=22718125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251330A Abandoned AU2001251330A1 (en) 2000-04-05 2001-04-05 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators

Country Status (8)

Country Link
US (1) US6528681B2 (fr)
EP (1) EP1268389B1 (fr)
JP (1) JP2004517033A (fr)
AT (1) ATE276995T1 (fr)
AU (1) AU2001251330A1 (fr)
CA (1) CA2403144A1 (fr)
DE (1) DE60105785D1 (fr)
WO (1) WO2001077057A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6180731A (ja) * 1984-09-28 1986-04-24 Toshiba Corp 管球の製造方法
SK602004A3 (en) 2001-08-11 2004-11-03 Bristol Myers Squibb Pharma Co Selective estrogen receptor modulators
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
ATE399775T1 (de) 2003-10-08 2008-07-15 Smithkline Beecham Corp Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
WO2009149081A1 (fr) * 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Procédé pour traiter les pathologies inflammatoires
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
SG11201405918XA (en) * 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9586952B2 (en) 2013-03-14 2017-03-07 Genentech, Inc. Polycyclic estrogen receptor modulators and uses thereof
CA2971216A1 (fr) 2014-12-23 2016-06-30 The Regents Of The University Of California Procedes d'immunomodulation de cancer et therapie de maladie infectieuse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
EE200000077A (et) 1997-08-15 2000-12-15 Duke University Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod

Also Published As

Publication number Publication date
US20020013297A1 (en) 2002-01-31
WO2001077057A2 (fr) 2001-10-18
DE60105785D1 (de) 2004-10-28
WO2001077057A3 (fr) 2002-06-13
ATE276995T1 (de) 2004-10-15
CA2403144A1 (fr) 2001-10-18
JP2004517033A (ja) 2004-06-10
US6528681B2 (en) 2003-03-04
EP1268389B1 (fr) 2004-09-22
EP1268389A2 (fr) 2003-01-02

Similar Documents

Publication Publication Date Title
US6927224B2 (en) Selective estrogen receptor modulators
EP1268389B1 (fr) Derives de triphenylethylene halogene utiles en tant que modulateurs selectifs vis-a-vis du recepteur des oestrogenes
CN102574843B (zh) 抗纤维化剂的稠环类似物
CA2777152C (fr) Acides 3-phenylpropioniques substitues et leur utilisation
AU2011340721A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
JPH09512830A (ja) レチノイン酸ｘ受容体リガンド
CN103086935A (zh) 二苯硒醚、二苯硒亚砜、二苯硒砜类化合物及其用途
EP1268387B1 (fr) Formes de sels specifiques de derives de triphenylethylene utilises comme modulateurs selectifs des recepteurs d'oestrogenes
Alam et al. Discovery of (S)-flurbiprofen-based novel azine derivatives as prostaglandin endoperoxide synthase-II inhibitors: Synthesis, in-vivo analgesic, anti-inflammatory activities, and their molecular docking
AU2001253191A1 (en) Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
JPH04501409A (ja) 抗アンドロゲン化合物
EP0082109A2 (fr) Acides 2-hydroxyphénylacétiques substitués et leurs dérivés
WO2017189865A1 (fr) Composés lipidiques de type furane, pyrrole, et thiophène destinés à être utilisés dans le traitement de la vaginite atrophique
JP2002511053A (ja) レチノイド型四環芳香族化合物の製造方法及び利用
JP3139690B2 (ja) 発癌予防剤
DE2509891A1 (de) Phenoxyphenylbuttersaeure-derivate und verfahren zu ihrer herstellung
WO1997026237A1 (fr) Derives polycycliques aromatiques de type retinoide, leur procede de preparation et leur utilisation pour la fabrication de compositions pharmaceutiques et cosmetiques
DE2709268A1 (de) Diphenylaetherderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen enthaltend diese verbindungen